Jinhe Biotechnology EBITDA vs. Current Valuation
| 002688 Stock | 4.59 0.04 0.88% |
EBITDA | First Reported 2010-12-31 | Previous Quarter 369.5 M | Current Value 356.4 M | Quarterly Volatility 47.3 M |
For Jinhe Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Jinhe Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Jinhe Biotechnology Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Jinhe Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Jinhe Biotechnology Co over time as well as its relative position and ranking within its peers.
Jinhe |
Jinhe Biotechnology Current Valuation vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Jinhe Biotechnology's current stock value. Our valuation model uses many indicators to compare Jinhe Biotechnology value to that of its competitors to determine the firm's financial worth. Jinhe Biotechnology Co is number one stock in ebitda category among its peers. It also is the top company in current valuation category among its peers reporting about 13.27 of Current Valuation per EBITDA. At present, Jinhe Biotechnology's EBITDA is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all model that can be used if you cannot value Jinhe Biotechnology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Jinhe Biotechnology's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Jinhe Current Valuation vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Jinhe Biotechnology |
| = | 387.55 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Jinhe Biotechnology |
| = | 5.14 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Jinhe Current Valuation vs Competition
Jinhe Biotechnology Co is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 51.92 Billion. Jinhe Biotechnology holds roughly 5.14 Billion in current valuation claiming about 10% of equities under Health Care industry.
Jinhe Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Jinhe Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Jinhe Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Jinhe Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Jinhe Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 170 M | 155.2 M | |
| Operating Income | 187.7 M | 167.7 M | |
| Income Before Tax | 101.5 M | 139.9 M | |
| Net Income Applicable To Common Shares | 86.9 M | 112.1 M | |
| Net Income | 86.5 M | 111 M | |
| Income Tax Expense | 924.9 K | 878.7 K | |
| Net Income From Continuing Ops | 94.4 M | 109.2 M | |
| Total Other Income Expense Net | 51 M | 53.5 M | |
| Net Interest Income | 13.9 M | 14.6 M | |
| Interest Income | 8.4 M | 8.8 M | |
| Change To Netincome | 76.2 M | 79.2 M |
Jinhe Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Jinhe Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Jinhe Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Jinhe Biotechnology's important profitability drivers and their relationship over time.
Use Jinhe Biotechnology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Jinhe Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Jinhe Biotechnology will appreciate offsetting losses from the drop in the long position's value.Jinhe Biotechnology Pair Trading
Jinhe Biotechnology Co Pair Trading Analysis
The ability to find closely correlated positions to Jinhe Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jinhe Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jinhe Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jinhe Biotechnology Co to buy it.
The correlation of Jinhe Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jinhe Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jinhe Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Jinhe Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Jinhe Biotechnology position
In addition to having Jinhe Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Conservative Funds Thematic Idea Now
Conservative Funds
Funds or Etfs that invest using buy-and-hold investment strategy in companies with consistent growth over many years of operation. The Conservative Funds theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Conservative Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Jinhe Stock
To fully project Jinhe Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Jinhe Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Jinhe Biotechnology's income statement, its balance sheet, and the statement of cash flows.